key: cord-0737741-ubbkq37o
authors: O’Connor, Christopher M.
title: Convalescence From COVID Research: Lessons From the Heart Failure Community
date: 2020-09-28
journal: JACC Heart Fail
DOI: 10.1016/j.jchf.2020.08.005
sha: a2c43120e616ad53a69398d4533c2201a9f4ee4b
doc_id: 737741
cord_uid: ubbkq37o

nan

Lessons From the Heart Failure Community these trials showed attenuated benefit and no effect on mortality.

What if we lived in a world in which these principles had been adopted early in the U.S. COVID-19

pandemic? The National Health Service investigators in the United Kingdom did so with several-fold fewer COVID cases and were able to answer many important questions regarding therapies, both positive and negative. As we begin to convalesce and recover from COVID-19, let us reflect on the great lessons we learned over a long and reflective journey of heart failure clinical trials, which, as a community, we can be proud. 

Food and Drug Administration. Clinical memorandum

Mortality and morbidity in patients receiving encainide, flecainide, or placebo -the cardiac arrhythmia suppression trial

A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure

Effect of amlodipine on the survival of patients with severe chronic heart failure due to a nonischemic cardiomyopathy: results of the PRAISE-2 study (prospective randomized amlodipine survival evaluation 2)